Efficacy and safety of ospemifene in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women: A phase II dose ranging, 12-week, randomized , double-blind, placebo-controlled, parallel-group study comparing oral ospemifene 5 mg, 15 mg and 30 mg daily doses with placebo.

Trial Profile

Efficacy and safety of ospemifene in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women: A phase II dose ranging, 12-week, randomized , double-blind, placebo-controlled, parallel-group study comparing oral ospemifene 5 mg, 15 mg and 30 mg daily doses with placebo.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Ospemifene (Primary)
  • Indications Atrophic vaginitis
  • Focus Therapeutic Use
  • Acronyms VVA-study
  • Sponsors Hormos Medical; Shionogi
  • Most Recent Events

    • 29 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top